Empery Asset Management’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Empery Asset Management’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17K	Hold	175,000	–	–	0.1%	63
2022 Q2	$19K	Hold	175,000	–	–	0.1%	56
2022 Q1	$28K	Hold	175,000	–	–	0.13%	61
2021 Q4	$75K	Buy	+175,000	New	+$138K	0.16%	46

Other funds holding DRMAW

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Empery Asset Management's DRMAW Position: Q3 2022 in Review

Empery Asset Management held its Dermata Therapeutics Warrant (DRMAW) position steady in Q3 2022 at 175,000 shares worth $17K. The position accounts for 0.1% of the portfolio, ranked #63.

Empery Asset Management first reported a position in DRMAW in Q4 2021 and has held it in 4 quarters since. The position peaked at $75K in Q4 2021. 5 funds tracked by Wall St. Rank hold DRMAW as of Q3 2022.

Empery Asset Management held 175,000 shares of Dermata Therapeutics Warrant worth $17K as of Q3 2022.
Empery Asset Management left its Dermata Therapeutics Warrant share count unchanged in Q3 2022.
Dermata Therapeutics Warrant made up 0.1% of Empery Asset Management's portfolio in Q3 2022, its #63 holding.
Empery Asset Management first reported a position in Dermata Therapeutics Warrant in Q4 2021 and has held it in 4 quarters since.
Empery Asset Management's Dermata Therapeutics Warrant position peaked at $75K in Q4 2021.
5 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q3 2022.

Based on Empery Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.